Predicting effects of methylphenidate and sulpiride on brain and cognition: A pharmaco-fMRI, PET study. Design and descriptives.
The large variation observed in the effects of dopaminergic drugs poses a major problem for neuropsychiatry, where therapeutic drugs may be ineffective or detrimental in a proportion of patients, but also for the healthy population. We have conducted a pharmaco-fMRI/PET study in 100 healthy participants to investigate the neural and neurochemical mechanisms of this variability. We studied the cognitive effects of methylphenidate (20mg) and sulpiride (400mg) across various cognitive domains, such as reward learning and motivation, working memory and effort motivation. To establish the baseline dopamine-dependency of the drug effects, all participants underwent an [18F]DOPA positron emission tomography scan on a separate off-drug session to quantify their baseline striatal dopamine synthesis capacity. In addition, multiple putative proxy measures of striatal dopamine activity were acquired, including spontaneous eye blink rate, trait impulsivity, subjective reward sensitivity and working memory capacity. The drug effects on each of the cognitive paradigms and their potential dependency on dopamine synthesis capacity and putative proxy measures are reported in separate papers. In the present paper, we report the design of the full study, as well as drug effects on subjective mood and autonomic arousal. This report aims to serve as a reference for future pharmacological fMRI/PET studies as well as for the specific papers resulting from detailed analyses of the included cognitive paradigms. The study will enable the development of a proxy-model of baseline dopamine, intended to provide a pragmatic handle on predicting the effects of dopaminergic drugs on brain and cognition that maximally generalizes to new participants.